Skip to content

Theravance Biopharma TBPH Other operating expenses

Other operating expenses at other companies

Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
-$279K+93.7%
Precigen logo
PrecigenPGEN
$29.25M+22.2%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$949.35M+649%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$37.68M+18.2%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$87.92M+20.0%
XOMA Corporation logo
XOMA CorporationXOMA
$12.8M+28.2%

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$890.32M+67.5%
Enterprise value$642.72M+37.0%
P/E7.8×
P/S8.1×0.0×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's other operating expenses?
Theravance Biopharma (TBPH) reported other operating expenses of $27.18M in Q1 2026.
How has Theravance Biopharma's other operating expenses changed year-over-year?
Theravance Biopharma's other operating expenses decreased by 8.9% year-over-year, from $29.82M to $27.18M.
What is the long-term trend for Theravance Biopharma's other operating expenses?
Over 4 years (2021 to 2025), Theravance Biopharma's other operating expenses has grown at a -22.8% compound annual growth rate (CAGR), from $313.1M to $111.07M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.